

**BS EN ISO 11980:2012**

*Incorporating corrigendum December 2012*



**BSI Standards Publication**

**Ophthalmic optics —  
Contact lenses and contact  
lens care products —  
Guidance for clinical  
investigations**

**bsi.**

...making excellence a habit.™

### National foreword

This British Standard is the UK implementation of EN ISO 11980:2012. It is identical to ISO 11980:2012, incorporating corrigendum December 2012. It supersedes BS EN ISO 11980:2009 which is withdrawn.

The UK participation in its preparation was entrusted by Technical Committee CH/172, Ophthalmic optics, to Subcommittee CH/172/9, Contact lenses and contact lens care products.

A list of organizations represented on this subcommittee can be obtained on request to its secretary.

This publication does not purport to include all the necessary provisions of a contract. Users are responsible for its correct application.

© The British Standards Institution 2013.

Published by BSI Standards Limited 2013

ISBN 978 0 580 81665 9

ICS 11.040.70

### **Compliance with a British Standard cannot confer immunity from legal obligations.**

This British Standard was published under the authority of the Standards Policy and Strategy Committee on 31 December 2012.

### **Amendments/corrigenda issued since publication**

Date	Text affected
31 October 2013	Implementation of ISO corrigendum December 2012: Standard replaced with ISO corrected version

English Version

**Ophthalmic optics - Contact lenses and contact lens care  
products - Guidance for clinical investigations (ISO 11980:2012)**

Optique ophtalmique - Lentilles de contact et produits  
d'entretien pour lentilles de contact - Directives pour les  
investigations cliniques (ISO 11980:2012)

Augenoptik - Kontaktlinsen und Kontaktlinsenpflegemittel -  
Leitfaden für die klinische Prüfung (ISO 11980:2012)

This European Standard was approved by CEN on 14 November 2012.

CEN members are bound to comply with the CEN/CENELEC Internal Regulations which stipulate the conditions for giving this European Standard the status of a national standard without any alteration. Up-to-date lists and bibliographical references concerning such national standards may be obtained on application to the CEN-CENELEC Management Centre or to any CEN member.

This European Standard exists in three official versions (English, French, German). A version in any other language made by translation under the responsibility of a CEN member into its own language and notified to the CEN-CENELEC Management Centre has the same status as the official versions.

CEN members are the national standards bodies of Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and United Kingdom.



EUROPEAN COMMITTEE FOR STANDARDIZATION  
COMITÉ EUROPÉEN DE NORMALISATION  
EUROPÄISCHES KOMITEE FÜR NORMUNG

**Management Centre: Avenue Marnix 17, B-1000 Brussels**

## **Foreword**

This document (EN ISO 11980:2012) has been prepared by Technical Committee ISO/TC 172 "Optics and photonics" in collaboration with Technical Committee CEN/TC 170 "Ophthalmic optics" the secretariat of which is held by DIN.

This European Standard shall be given the status of a national standard, either by publication of an identical text or by endorsement, at the latest by May 2013, and conflicting national standards shall be withdrawn at the latest by May 2013.

Attention is drawn to the possibility that some of the elements of this document may be the subject of patent rights. CEN [and/or CENELEC] shall not be held responsible for identifying any or all such patent rights.

This document supersedes EN ISO 11980:2009.

According to the CEN/CENELEC Internal Regulations, the national standards organisations of the following countries are bound to implement this European Standard: Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, Former Yugoslav Republic of Macedonia, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Norway, Poland, Portugal, Romania, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey and the United Kingdom.

### **Endorsement notice**

The text of ISO 11980:2012 has been approved by CEN as a EN ISO 11980:2012 without any modification.

<b>Contents</b>		Page
<b>Introduction</b> .....		iv
<b>1</b>	<b>Scope</b> .....	1
<b>2</b>	<b>Normative references</b> .....	1
<b>3</b>	<b>Terms and definitions</b> .....	1
<b>4</b>	<b>Clinical investigational requirements</b> .....	1
<b>4.1</b>	<b>General</b> .....	1
<b>4.2</b>	<b>Additional requirements</b> .....	1
<b>4.3</b>	<b>Other considerations</b> .....	4
<b>Annex A</b> (informative) <b>Elements of a clinical investigation</b> .....		5
<b>Annex B</b> (informative) <b>Procedures for the evaluation of safety, physiological performance and effect on ocular tissues</b> .....		18
<b>Annex C</b> (informative) <b>The evaluation of visual, refractive and lens performance and subject acceptance</b> .....		23
<b>Bibliography</b> .....		26

## **Introduction**

Currently, contact lenses and contact lens care products are regulated in different ways in different countries. This International Standard has been developed to encourage global harmonization. Widespread adoption of this International Standard should represent yet another step toward mutual recognition. This International Standard can also be used as a basis to fulfil design elements of ISO 9001<sup>[1]</sup>.

# Ophthalmic optics — Contact lenses and contact lens care products — Guidance for clinical investigations

## 1 Scope

This International Standard gives guidelines for the clinical investigation (CI) of the safety and performance of contact lenses and contact lens care products.

**NOTE** This International Standard attempts to harmonize the recognized regulatory requirements for the conduct of a CI to meet the marketing and labelling requirements for contact lenses and contact lens care products around the world. However, national requirements vary greatly. Wherever national practice or regulations dictate some legal requirement, this requirement takes precedence over this International Standard.

## 2 Normative references

The following referenced documents are indispensable for the application of this document. For dated references, only the edition cited applies. For undated references, the latest edition of the referenced document (including any amendments) applies.

ISO 14155, *Clinical investigation of medical devices for human subjects — Good clinical practice*

ISO 14534, *Ophthalmic optics — Contact lenses and contact lens care products — Fundamental requirements*

ISO 18369-1, *Ophthalmic optics — Contact lenses — Part 1: Vocabulary, classification system and recommendations for labelling specifications*

## 3 Terms and definitions

For the purposes of this document, the terms and definitions given in ISO 14155, ISO 14534 and ISO 18369-1 apply.

## 4 Clinical investigational requirements

### 4.1 General

The general requirements for a CI and for a clinical investigation plan (CIP) given in ISO 14155 shall apply, with additional requirements given below.

### 4.2 Additional requirements

#### 4.2.1 Study design

##### 4.2.1.1 General

- a) The inclusion criteria for subject selection shall relate to the study objectives and should include:
  - 1) subjects with normal eyes who are not using any ocular medications, aged 18 years or over [except when contact lens investigations have a special indication for use in “children” (for the purposes of this International Standard, persons less than 18 years of age) such as orthokeratology and paediatric aphakic lenses];
  - 2) lens powers within the range available for the test lenses;
  - 3) the manifest cylinder less than or equal to 0,75 D (for a study with only spherical power correcting lenses);

- 4) best spectacle corrected visual acuity greater than or equal to 20/25 (less than or equal to LogMAR 0,1).
- b) The exclusion criteria for subject selection shall relate to the study objectives and should include, but not be limited to:
- 1) anterior segment infection, inflammation or abnormality;
  - 2) any active anterior segment ocular disease that would contraindicate contact lens wear;
  - 3) the use of systemic or ocular medications that would contraindicate contact lens wear;
  - 4) history of herpetic keratitis;
  - 5) history of refractive surgery or irregular cornea (except when the contact lenses under investigation are indicated for irregular cornea, keratoconus or refractive surgery);
  - 6) slit lamp findings that are more serious than grade 1;
  - 7) corneal vascularization greater than 1 mm of penetration;
  - 8) a pathologically dry eye;
  - 9) participation of the subject in a contact lens or contact lens care product clinical trial within the previous 30 days.
- c) The CIP shall provide a description of the monitoring procedure to ensure consistent quality of data collection and recording.
- d) The CIP shall include a statistical analysis plan. Sample size shall be justified, calculated by a validated statistical software package.

#### **4.2.1.2 Contact lenses**

**4.2.1.2.1 General.** A CI of contact lenses, including daily wear and extended wear hydrogel, silicone hydrogel, and rigid gas-permeable contact lenses, shall be designed as one of 4.2.1.2.2 or 4.2.1.2.3.

For CIPs to demonstrate safety and performance, as well as special claims (e.g. comfort), labelling or additional indications, the following is required: a pre-determined statistical analysis plan (including sample size calculations) shall be specified in the clinical protocol. Where feasible, the CIP shall define objective endpoints to help support such claims.

NOTE 1 Inter-subject controls are preferred to intra-subject controls due to the potential dependence between the two eyes and concerns regarding subject compliance.

NOTE 2 Annex A provides guidance for the design of a CI.

**4.2.1.2.2 As a prospective, concurrently controlled study.** For investigations evaluating hydrogel, silicone hydrogel or rigid gas-permeable contact lenses, a prospective, concurrent control study design shall be followed. Either a bilateral crossover design or a contra-lateral eye (i.e. intra-subject) design or inter-subject controls shall be utilized. If inter-subject controls are utilized, the ratio of test subjects to control subjects may be either 2:1 or 1:1. The control lens shall be a currently marketed contact lens in use for the same modality. Randomization and masking (subject, investigator and evaluator) shall be employed where possible to minimize the potential for bias. Subjects shall be divided evenly between study investigators.

**4.2.1.2.3 As an uncontrolled study.** Here, results are compared to a historical control. Alternative investigational study designs, such as historical controls, shall be utilized when a sponsor has a clinical database on a marketed contact lens to use as a comparator. If any historical control is used, the control group shall be defined and adequately characterized for comparison to the test group. Compatibility of test and control groups shall be demonstrated by comparison of the selection criteria, demographics, refractive characteristics, contact lens wearing history and CIPs used.



#### 4.2.1.3 Contact lens care products

For investigations evaluating contact lens care products, a prospective concurrent control study design shall be followed. It is recommended that the ratio of test to control subjects be either 2:1 or 1:1. The control care product shall be a currently marketed contact lens care product. Randomization and masking (subject, investigator and evaluator) shall be employed where possible to minimize the potential for bias. Subjects shall be divided evenly between study investigators. Alternative investigational study designs, such as use of historical controls, may be utilized when a manufacturer has a clinical database on a marketed care product to use for comparison. If any historical control is used, the control group should be defined and adequately characterized for comparison to the test group. Compatibility of test and control groups should be demonstrated by comparison of the selection criteria and CIPs used.

For CIPs to demonstrate safety and performance, as well as special claims (e.g. comfort), labelling or additional indications, the following is required for the care products: a pre-determined statistical analysis plan (including sample size calculations) shall be specified in the clinical protocol. Where feasible, the protocol should define objective endpoints to help support such claims.

NOTE 1 Inter-subject controls are preferred to intra-subject controls due to the potential dependence between the two eyes and concerns regarding subject compliance.

In a contact lens care product investigation, a daily wear schedule shall be followed for most products in order to maximize the subject's exposure to those products. However, a study of a lens or a periodic cleaner, used at weekly intervals, may provide more valuable clinical data concerning efficacy when extended wear subjects are enrolled than a similar investigation with daily wear subjects.

When a daily wear schedule is used and safety is a primary objective, one post-dispensing visit should be done 1 h to 2 h after lens insertion in order to permit observation of corneal and conjunctival staining caused by an immediate toxicity reaction.

A contact lens care product with a cleaning indication shall have an objective measure of lens cleanliness on at least one lens collected from each subject at the end of the clinical study.

If the manufacturer of a contact lens care product wishes to recommend its use with a specific type of lens in the labelling, the compatibility with the lens type should be confirmed pre-clinically and during the clinical trial.

If the CI has not collected any data on use with a particular type of lens material (such as silicone hydrogel lenses), the product label should clearly state this fact.

NOTE 2 Annex A provides guidance for the design of a CI.

#### 4.2.2 Variables

##### 4.2.2.1 Contact lenses

The following variables should be considered during the CI for contact lenses, in addition to the variables listed in 4.2.2.2:

- a) visual performance;
- b) refractive performance;
- c) keratometric measurements;
- d) lens centration;
- e) lens movement;
- f) lens surface wettability;
- g) lens surface deposits;
- h) subject acceptance of comfort;

- i) subject acceptance of vision;
- j) subject acceptance of handling.

Additional variables can be studied in the CI to support specific claims.

NOTE Annex C provides guidance on classifications for each of these variables.

#### **4.2.2.2 Contact lens care products**

The following variables should be assessed during the CI for contact lens care products:

- a) corneal oedema;
- b) corneal infiltrates;
- c) endothelial irregularity;
- d) corneal vascularization;
- e) corneal staining;
- f) conjunctival observations;
- g) palpebral conjunctival observations;
- h) corneal ulcers;
- i) corneal opacification;
- j) hyphema;
- k) hypopyon;
- l) iritis;
- m) corneal scarring.

Additional variables can be studied in the CI to support specific claims.

NOTE Annex B provides guidance on classifications for some of these variables.

#### **4.3 Other considerations**

Serious ophthalmic adverse events and all adverse device effects shall be reported using a special case report form and forwarded to the sponsor as required. All other ophthalmic adverse events shall be reported using the standard visit case report forms and shall be collected during monitoring.

## Annex A (informative)

### Elements of a clinical investigation

#### A.1 General

The following are elements of a CIP which can assist in collecting data for the purpose of determining the safety and performance of contact lenses and contact lens care products.

#### A.2 Study size and duration

##### A.2.1 Contact lens investigations

**Table A.1 — Guide to the subject numbers (completed subjects) suggested for contact lens clinical investigations (informative)**

Wearing modality	Subject number completed per group at end of trial	Duration	Material and design
Daily wear	50	3 months	Containing new or new ratio material components; significant design changes
	30	30 days	All materials and designs
Daily wear orthokeratology	50	3 months or longer if necessary to reach defined stability	All materials and designs
Extended wear, up to 7 days	160	12 months	All materials and designs
Extended wear, up to 30 days	570	12 months	All materials and designs
Overnight wear (may include orthokeratology)	100 pre-market/ 200 post-market	6 months	All materials and designs

##### A.2.2 Contact lens care product investigations

**A.2.2.1** Contact lens care products, including saline solutions, daily cleaners, periodic cleaners, disinfecting solutions, neutralizers, “in-eye” solutions, conditioning solutions, and multipurpose solutions that have any new active ingredient, or any active ingredient outside the concentration range used in a comparable marketed product, should undergo a 3 month clinical study.

**A.2.2.2** Products for use with soft (hydrophilic) lenses: sample size (completed) should be 30 subjects in the test solution and 15 subjects in the control solution (a currently marketed solution for the same indication) for each appropriate representative category such as:

- Group I;
- Group IV;
- A separate group for each silicone hydrogel lens. If more than one lens is made by a given manufacturer, and they all have the same general chemistry, it is sufficient to use only the lens of highest water content.

**A.2.2.3** Products for use with rigid lenses: sample size (completed) should be 15 or 30 subjects using the test solution and 15 subjects using the control solution (a currently marketed solution for the same indication) for each appropriate material group.

**A.2.2.4** For a contact lens solution that does not contain any new active ingredients (as described in A.2.2.1), but contains any active ingredient lower than the concentration range used in a comparable marketed product, a 1 month clinical study should be conducted. In this case, the sample size should be about half of that recommended in A.2.2.2 and A.2.2.3, using the same general distribution of subjects.

### A.2.3 Statistical considerations for extended wear evaluations

#### A.2.3.1 General

Primary safety analysis: the key safety endpoint should be the frequency of serious and significant adverse events.

The null hypothesis,  $H_0$ , is that the test rate of endpoint adverse events,  $p_t$ , minus the control rate of endpoint adverse events,  $p_c$ , is greater than or equal to the clinically insignificant difference,  $\delta$ , between the two rates.

The alternative hypothesis,  $H_a$ , is that the test rate of endpoint adverse events,  $p_t$ , minus the control rate of endpoint adverse events,  $p_c$ , is less than a clinically insignificant difference,  $\delta$ , between the two rates.

$$H_0: p_t - p_c \geq \delta$$

$$H_a: p_t - p_c < \delta$$

where

$p_t$  is the proportion in the test population;

$p_c$  is the proportion in the control population.

When using a 1:1 ratio of patient allocation between treatment and control, the minimum number,  $n$ , of completed patients necessary for each treatment group is determined by:

$$n = \frac{(Z_{1-\beta} + Z_{1-\alpha})^2 \times [p_t(1-p_t) + p_c(1-p_c)]}{\delta^2}$$

where

$\alpha$  is the significance level (also known as the type 1 error rate);

$1 - \beta$  is the power of the test;

$Z$  is the standard normal quantile.

The following is an example of the calculation that makes assumptions found to be reasonable for clinical studies of 7 day extended wear hydrogel or silicone hydrogel contact lenses. With a control rate,  $p_c$ , and a

test rate,  $p_t$ , of 0,033 (under  $H_a$ ), a clinically insignificant difference,  $\delta$ , of 0,05, a power,  $1 - \beta$ , of 0,80, and a significance level,  $\alpha$ , of 0,05, the minimum number of completed patients per treatment group is:

$$n = \frac{(0,84 + 1,64)^2 \times [0,033 \times (1 - 0,033) + 0,033 \times (1 - 0,033)]}{0,05^2} \approx 158$$

This equation is only valid when it is assumed for the alternative hypothesis,  $H_a$ , that the test rate of adverse events is equal to the control rate,  $p_t = p_c$ . When this is not a valid assumption, the following equation can be used to provide an approximate calculation for the sample size:

$$n = \frac{(Z_{1-\beta} + Z_{1-\alpha})^2 \times [p_t(1 - p_t) + p_c(1 - p_c)]}{(p_t - p_c - \delta)^2}$$

For clinical studies of 30 day extended wear hydrogel contact lenses, it is recommended that a 7 day extended wear lens (worn for up to 6 nights/7 days) be used as the control. The following is an example of the calculation that makes assumptions found to be reasonable for many clinical studies of 30 day extended wear hydrogel contact lenses. With a control rate,  $p_c$ , of 0,033 and a test rate,  $p_t$ , of 0,053 (under  $H_a$ ), a clinically insignificant difference,  $\delta$ , of 0,05, a power,  $1 - \beta$ , of 0,80, and a significance level,  $\alpha$ , of 0,05, the minimum number of completed subjects per treatment group is:

$$n = \frac{(0,84 + 1,64)^2 \times [0,053 \times (1 - 0,053) + 0,033 \times (1 - 0,033)]}{(0,053 - 0,033 - 0,05)^2} \approx 562$$

Enrolment should be adjusted to compensate for drop-out which is typically 20 % to 25 % in 1 year contact lens studies. Therefore, for the above example of a clinical study of a 7 day extended wear contact lens, the recommended sample size would be adjusted to approximately 215 per subject group. For the above example of a study of a 30 day extended wear lens, the recommended sample size would be approximately 760 per subject group.

At the conclusion of the study, sensitivity analyses (e.g. multiple imputation analyses) should be conducted to evaluate the robustness of the study result accounting for missing observations, if there is more than minimal subject drop-out.

### A.2.3.2 Daily wear hydrogel, silicone hydrogel or rigid gas-permeable contact lens evaluations

Sample sizes are designed to give reasonable assurance of obtaining at least one complication, as a function of the expected complication rate (i.e. 5 % for a 60 subject test group, 10 % with a 30 subject test group), with a probability of greater than 95 %. Therefore, in a subject group of 30 (completed) subjects exposed to a short-term duration (90 days) of a test product, an adverse event occurrence in two to three subjects may cause concern as to the biocompatibility and fundamental safety of the device being tested. Any investigation resulting in more than one adverse reaction should include adequate justification in order to establish safety and efficacy.

### A.2.3.3 Contact lens care product evaluations

Clinical sample sizes are designed so that there is 95 % confidence that a study has at least one complication in a material category, if the true complication rate is  $\geq 10$  %. This implies that a study should have at least 30 (completed) subjects exposed to a short-term duration (90 days) of a test care product, for each material grouping. Studies should include all material groupings of interest for the product.

Any investigation resulting in more than one adverse reaction should include adequate justification in order to establish safety and efficacy.

## A.2.4 Adverse events and adverse device effects

### A.2.4.1 General

Adverse events should be differentiated into device related and non-device related. Any corneal infiltrate, ulcer, neovascularization, etc. shall be presumed to be device related unless the case history clearly indicates some other origin. All corneal ulcers shall be recorded in the study report.

### A.2.4.2 Serious adverse events

Serious adverse events are those events that result in, or have potential to cause, either permanent impairment of an ocular function or damage to an ocular structure, and may necessitate medical or surgical intervention.

Serious adverse events may include any hazardous, sight-threatening conditions occurring after exposure to test article, including but not limited to the following.

- a) A presumed infectious ulcer (defined as a progressive erosion of the corneal tissue). Signs may include irregular focal infiltrates (> 1 mm); active lesions with raised edges; significant diffuse infiltration; anterior corneal to mid-stromal involvement; erosion with overlying staining; conjunctival and lid oedema; anterior chamber reaction (iritis); severe bulbar and limbal redness. Symptoms associated with a presumed infectious ulcer (microbial keratitis) may include pain of rapid onset; severe redness; purulent or mucopurulent discharge; tearing; photophobia. For the purposes of reporting, a corneal ulcer which has *any* of the following characteristics should be considered in this category:
  - 1) central or paracentral location;
  - 2) penetration of Bowman's membrane;
  - 3) infiltrate > 2 mm diameter;
  - 4) associated with iritis  $\geq$  grade 2;
  - 5) associated with any increase in intraocular pressure;
  - 6) culture positive for microorganisms;
  - 7) increasing size or severity at subsequent visits.
- b) Any central or paracentral corneal event (such as vascularization) that results in permanent opacification.
- c) Any serious adverse ophthalmic events including hypopyon and hyphema.
- d) Any neovascularization within the central 6 mm of the cornea.
- e) The loss of two or more lines of visual acuity that fail to resolve.
- f) All cases of iritis.

Significant but non-serious adverse events should include, but not be limited to:

- peripheral non-progressive non-infectious ulcers;
- all symptomatic corneal infiltrative events;
- all cases of corneal staining greater than or equal to grade 3;
- a temporary loss of two or more lines of best corrected visual acuity (for greater than or equal to 2 weeks);
- cases greater than or equal to grade 2 neovascularization;
- any ocular event that necessitates temporary lens discontinuation of greater than or equal to 2 weeks.

### A.3 Reporting of results

Tables A.2 to A.12 give guidance for sample tables of results. Separate tables may be used for test and control groups. Not all tables apply to studies for all product categories.

**Table A.2 — Accountability by eyes enrolled in the study and distribution status**

Status	Number of eyes	
	Control eyes $N_C$	Trial eyes $N_T$
<b>Enrolled dispensed</b>		
Completed	$N_C$	$N_T$
Active lens wearers (visit completed)		
dispensed	$N_C$	$N_T$
1st follow-up	$N_C$	$N_T$
2nd follow-up	$N_C$	$N_T$
(list through $n$ th follow-up)		
Discontinued	$N_C$	$N_T$
Lost to follow-up (no-show)	$N_C$	$N_T$
<b>Enrolled not dispensed</b>	$N_C$	$N_T$
<b>Total enrolled</b>	$N_C$	$N_T$

**Table A.3 — Tabulation of eyes by most recent lens-wearing experience and demographics**

Total	Eyes				Subtotal
	Rigid lens	Hydrogel lens	Silicone hydrogel lens	Other	
Previous experience unreported					
No prior lens experience					
New wearers (less than 2 months' wear)					
Previous wearers: most recent experience					
Successful:					
daily wear					
extended wear					
Unsuccessful:					
daily wear					
extended wear					
Total lens wearers					
Total enrolled					
Demographics					
Age of patients:	From	to	Average:		
Sex:	Female:	Male:	Ratio:		
Lens power range: (maxima)	+	D			
	-	D			
	Cylinder	D			



Table A.4 — Adverse events

Non-device related							
Adverse event	Time in investigation (from dispensing)	Date first seen by investigator	Date of resolution	Intervention	Subject discontinued?	Severity	Outcome
1							
2							
3							
4							
etc.							
Total number of non-device-related adverse events:							
Device related							
Adverse device event (ADE)	Time in investigation (from dispensing)	Date first seen by investigator	Date of resolution	Intervention	Subject discontinued?	Severity	Outcome
1							
2							
3							
4							
etc.							
Total eyes with adverse device events requiring treatment:							

Table A.5 — Slit lamp findings (example: epithelial oedema) by visit, tabulated by eyes and incidence rate

Epithelial oedema	Initial dispensing visit	Intermediate visits				Un-scheduled visits	Final visit
		1	2	3	4		
		No. %	No. %	No. %	No. %		
0 = none							
1 = trace							
2 = mild							
3 = moderate							
4 = severe							
<b>Total eyes</b>							

**Table A.6 — Symptoms, problems, and complaints (example: comfort) by visit, tabulated by eyes and incidence rate**

Total eyes at visit	Initial dispensing visit No. %	Intermediate visits				Un-scheduled visits No. %	Final visit No. %	Overall total No. %
		1 No. %	2 No. %	3 No. %	4 No. %			
<b>Comfort</b> 0 = excellent, cannot be felt 1 = very comfortable, just felt occasionally 2 = comfortable, noticeable but not irritating 3 = slightly uncomfortable, just irritating or annoying 4 = very uncomfortable, very irritating or annoying 5 = causes pain, lens cannot be tolerated								
<b>Total number positive reports:</b>								

**Table A.7 — Keratometry change (absolute value) from baseline to final visit by meridian**

Dioptres	Flattest		Steepest		Total eyes		
	No.	%	No.	%	No.	%	
0,00 D to 1,00 D <sup>a</sup>							
1,12 D to 1,50 D <sup>a</sup>							
1,62 D to 2,00 D <sup>a</sup>							
(continue as needed)							
Mean keratometry change:	D						
Minimum keratometry change:	D						
Maximum keratometry change:	D						
<b>Listing of vertical and horizontal keratometry readings and changes (absolute value) from baseline to final visit for eyes that changed by more than 1 D</b>							
Investigator	Patient	Eye	H/V	Baseline	Final <sup>b</sup> visit	Absolute change	Reason
1							
2							
3							
<sup>a</sup> Keratometric measurements can be reported in millimetres, where 1,00 D difference is equivalent to 0,20 mm difference. <sup>b</sup> Final study visit for completed subjects or exit visit for discontinued subjects.							

**Table A.8 — Spherical refractive changes (absolute value) from baseline to final visit**

Dioptres	Total eyes					
	No.	%				
0,00 D to 1,00 D 1,12 D to 1,50 D 1,62 D to 2,00 D (continue as needed)						
Mean refractive change:	D					
Minimum refractive change:	D					
Maximum refractive change:	D					
<b>Listing of refractive changes (absolute value) from baseline to final visit for eyes that changed by more than 1 D</b>						
Investigator	Patient	Eye	Baseline	Final visit	Absolute change	Reason
1						
2						
3						
etc.						

**Table A.9 — Visual acuity (VA) results<sup>1)</sup>**

With contact lens (no over-refraction) at final visit								
Initial best corrected contact lens visual acuity with spherical over-refraction	No. of eyes	20/15 LogMAR -0,1	20/20 LogMAR 0,0	20/25 LogMAR 0,1	20/30 LogMAR 0,2	20/40 LogMAR 0,3	Not reported	Total
		No. %	No. %	No. %	No. %	No. %	No. %	No. %
20/15 LogMAR -0,1								
20/20 LogMAR 0,0								
20/25 LogMAR 0,1								
20/30 LogMAR 0,2								
20/40 LogMAR 0,3								
(continue as needed)								
<b>Total</b>								
The percentage at each VA (or total), $p_{VA,i}$ , is given by								
$p_{VA,i} = \frac{\sum_{i=1}^n N_{e,i}}{N_{e,1}} \times 100$								
where								
$\sum_{i=1}^n N_{e,i}$								
is the number of eyes at each VA (or total);								
$N_{e,1}$ is the number of eyes at initial visit corrected of corresponding row.								

1) Table A.9 should be replicated for every scheduled study visit with contact lenses.

Table A.9 (continued)

<b>Visual acuity summary:</b>					
Number of eyes with initial best corrected VA of 20/30 or better:					
Number of eyes with final VA with lens of 20/30 or better:					
Number of eyes with final VA with lens within 1 LogMAR VA line (or Snellen equivalent) of best corrected:					
Number of eyes with final VA with lens of worse than 1 LogMAR VA line (or Snellen equivalent) of best corrected:					
<b>Listing of eyes that changed by two or more LogMAR VA lines (or Snellen equivalent)</b>					
Investigator	Patient	Eye	Initial VA	VA at visit	Reason
1					
2					
3, etc.					
<b>Best corrected visual acuity at subject's final visit with contact lenses or over-refraction</b>					
Initial best corrected	20/15 LogMAR -0,1 No. %	20/20 LogMAR 0,0 No. %	20/25 LogMAR 0,1 No. %	20/30 LogMAR 0,2 No. %	20/40 LogMAR 0,3 No. %
20/15 LogMAR -0,1 20/20 LogMAR 0,0 20/25 LogMAR 0,1 20/30 LogMAR 0,2 20/40 LogMAR 0,3					
<b>Best corrected visual acuity at subject's final visit with other means of correction</b>					
Initial best corrected	20/15 LogMAR -0,1 No. %	20/20 LogMAR 0,0 No. %	20/25 LogMAR 0,1 No. %	20/30 LogMAR 0,2 No. %	20/40 LogMAR 0,3 No. %
20/15 LogMAR -0,1 20/20 LogMAR 0,0 20/25 LogMAR 0,1 20/30 LogMAR 0,2 20/40 LogMAR 0,3					

Table A.10 — Average hours worn

Wearing time h	Intermediate visits				Unscheduled No. %	Final visit No. %
	1 No. %	2 No. %	3 No. %	4 No. %		
0 to 4,0						
> 4,0 to 6,0						
> 6,0 to 8,0						
> 8,0 to 10,0						
> 10,0 to 12,0						
> 12,0 to 14,0						
> 14,0 to 16,0						
> 16,0 to 18,0						
> 18,0						
Wearing time average/visit (hours)						

Table A.11 — Reasons for not completing the investigation

Reasons	Eye at (or after) visit completed						Aggregate eyes discontinued %
	Initial	Intermediate visits				Un-scheduled visit	
		1	2	3	4		
Visual acuity	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$(N_C/N_T)$
Vision							
Adverse device event							
Adverse reaction							
Lens position							
Discomfort							
Handling							
Disinterest							
Other (specify)							
<b>Subtotal</b>	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$(N_C/N_T)$
<b>Lost to follow-up</b>							
<b>Total</b>	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$(N_C/N_T)$
<p><math>N_C</math> is the number of control eyes  <math>N_T</math> is the number of trial eyes  The percentage incidence, <math>p_I</math>, is given by</p> $p_I = \frac{\sum N_{e, \text{disc}/\text{reason}}}{\sum N_{e, \text{comp}} + \sum N_{e, \text{disc}}} \times 100$ <p>where</p> <ul style="list-style-type: none"> <li><math>\sum N_{e, \text{disc}/\text{reason}}</math> represents the aggregate eyes discontinued per reason;</li> <li><math>\sum N_{e, \text{comp}}</math> represents the total eyes completed;</li> <li><math>\sum N_{e, \text{disc}}</math> represents the total eyes discontinued.</li> </ul>							
<p>NOTE Visual acuity is an objective assessment of the subject's vision (perception of how they see).</p>							

Table A.12 — Lens replacement by visit

For completed subjects							
Reason for replacement	Initial	Intermediate visits				Un-scheduled visits	Total
	No. %	1 No. %	2 No. %	3 No. %	4 No. %	No. %	No. %
Visual acuity	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$
Comfort							
Pathology							
Base curve							
Diameter							
Lost							
Torn							
Lens deposits							
Bad edge							
Bad surface							
Discoloration							
Other (specify)							
Total	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$

$N_C$  is the number of control eyes  
 $N_T$  is the number of trial eyes  
 Purpose: to provide a tabulation of all lenses replaced during the study by reason for replacement.  
 Lenses replaced for visual acuity, pathological or other physiological reasons should be listed individually, with the specific reason for replacement and the visual acuity with the replacement lens.  
 Number and percentage refer to the number of eyes for each reason for replacement for the corresponding row.  
 Percentage,  $p_{e, repl}$  should be calculated in accordance with

$$p_{e, repl} = \frac{N_{e,i}}{\sum_{i=1}^n N_{e,i}} \times 100$$

where  
 $N_{e,i}$  is the number of eyes at each visit;  
 $\sum_{i=1}^n N_{e,i}$  is the total number of eyes.

Table A.12 (continued)

For discontinued subjects							
Reason for replacement	Initial	Intermediate visits				Un-scheduled visits	Total
	No. %	1 No. %	2 No. %	3 No. %	4 No. %	No. %	No. %
Visual acuity	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$
Comfort							
Pathology							
Base curve							
Diameter							
Lost							
Torn							
Lens deposits							
Bad edge							
Bad surface							
Discoloration							
Other (specify)							
Total	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$	$N_C/N_T$

$N_C$  is the number of control eyes  
 $N_T$  is the number of trial eyes  
**Purpose:** to provide a tabulation of all lenses replaced during the study by reason for replacement.  
Lenses replaced for visual acuity, pathological or other physiological reasons should be listed individually, with the specific reason for replacement and the visual acuity with the replacement lens.  
Number and percentage refer to the number of eyes for each reason for replacement for the corresponding row. Percentage,  $p_{e, repl}$  should be calculated in accordance with  

$$p_{e, repl} = \frac{N_{e,i}}{\sum_{i=1}^n N_{e,i}} \times 100$$
where  
 $N_{e,i}$  is the number of eyes at each visit;  
 $\sum_{i=1}^n N_{e,i}$  is the total number of eyes.

NOTE Bad surface (note specific reasons in report form).

## Annex B (informative)

### Procedures for the evaluation of safety, physiological performance and effect on ocular tissues

#### B.1 General

The following classifications should be considered whenever the procedure is included in the CIP.

#### B.2 Corneal oedema

##### B.2.1 General

Corneal oedema should be classified separately for the epithelium and the stroma.

##### B.2.2 Epithelial oedema

Epithelial oedema should be classified according to the number of microcysts observed.

0 = none	no microcysts; normal transparency
1 = trace	1 to 20 microcysts; barely discernible local epithelial haziness
2 = mild	21 to 50 microcysts; faint but definite localized or generalized haziness
3 = moderate	51 to 100 microcysts; significant localized or generalized haziness
4 = severe	> 100 microcysts; definite widespread epithelial cloudiness giving a dull glass appearance to the cornea or numerous coalescing bullae.

The presence/absence of fluid-filled or debris-filled cysts should be documented, along with their numbers.

##### B.2.3 Stromal oedema

Stromal oedema should be classified according to the following scale:

0 = none	no oedema
1 = trace	just detectable clouding
2 = mild	faint corneal striae (2 or fewer)
3 = moderate	pronounced corneal striae (3)
4 = severe	folds in Descemet's membrane and $\geq 4$ pronounced striae.

#### B.3 Corneal infiltrates

The severity of corneal infiltrates should be classified according to the following scale:

0 = none	no infiltrates
1 = trace	single or multiple epithelial infiltrates < 1 mm in diameter



- |              |  |
|--------------|--|
| 2 = mild     | single or multiple epithelial infiltrates $\geq 1$ mm and $< 2$ mm in diameter |
| 3 = moderate | multiple infiltrates $\geq 2$ mm and $< 3$ mm in diameter                      |
| 4 = severe   | multiple dense infiltrates $\geq 3$ mm in diameter                             |


Location of corneal infiltrates in the cornea should be noted as indicated in Figure B.1.

Depth of corneal infiltrates should be abbreviated as follows:

E = epithelial

AS = anterior stromal

P = mid/posterior stromal



#### Key

R right eye

L left eye

1 C = central

2 S = superior

3 N = nasal

4 I = inferior

5 T = temporal

**Figure B.1 — Method for recording location in/on the cornea**

## B.4 Endothelial regularity

Endothelial regularity should be classified according to the following scale:

0 = regular endothelial mosaic

1 = isolated difference in cell size

2 = just noticeable variation in cell size or bumpiness of cell layer

3 = easily detected difference in cell size or bumpiness of cell layer

4 = noticeable cell layer bumpiness and loss of definition of cell borders

## B.5 Corneal vascularization

Maximal corneal vascularization should be reported according to the following scale:

0 = none no vessel penetration

1 = trace  $< 1,00$  mm vessel penetration

2 = mild	$\geq 1,00$ mm to $\leq 1,5$ mm vessel penetration
3 = moderate	$> 1,5$ mm to $\leq 2,00$ mm vessel penetration
4 = severe	vessel penetration $> 2,0$ mm

The depth and location of vessel penetration should be reported as follows:

Depth:	a) superficial
	b) stromal
Location:	N = nasal
	T = temporal
	I = inferior
	S = superior
	CL = circumlimbal
	X = other (describe)

## B.6 Corneal staining with fluorescein

Corneal staining should be recorded according to the following scale (see Notes 1 and 2 below):

0 = none	no staining
1 = trace	minimal superficial staining or punctate staining
	a) dimpling, discrete dot staining, or
	b) trace superficial lens insertion marks or foreign body tracks
2 = mild	regional or diffuse punctate staining
	a) central or generalized, or
	b) peripheral including 3 to 9 o'clock staining, or
	c) foreign body tracks
3 = moderate	dense coalescent staining up to 2 mm in diameter
	a) corneal abrasion
	b) foreign body track
4 = severe	dense coalescent staining greater than 2 mm in diameter
<input type="checkbox"/>	check box if staining is associated with an underlying infiltrate
<input type="checkbox"/>	check box if staining is NOT associated with an underlying infiltrate

The location of the staining observed should be recorded as indicated in Figure B.1. The preferred method for recording the location is by numbers (see Figure B.1).

NOTE 1 All corneal staining observations should be carried out using a blue excitation light in conjunction with a yellow barrier filter in the observation system.

NOTE 2 Recurrent erosion and corneal ulceration should be recorded under a section "Other complications".

## B.7 Conjunctival observations

Limbal hyperaemia should be recorded on a five-point scale as follows:

0 = none	no hyperaemia
1 = trace	slight limbal hyperaemia (mild segmented)
2 = mild	mild limbal hyperaemia (mild circumcorneal)
3 = moderate	significant limbal hyperaemia (marked segmented)
4 = severe	severe limbal hyperaemia (marked circumcorneal)

Bulbar conjunctival hyperaemia should be recorded on a five-point scale as follows:

0 = none	no hyperaemia
1 = trace	slight regional hyperaemia
2 = mild	diffuse hyperaemia
3 = moderate	marked regional or diffuse hyperaemia
4 = severe	diffuse episcleral or scleral hyperaemia

Bulbar conjunctival compression/indentation (0 = absence; 1 = presence):

right eye \_\_\_\_\_


left eye \_\_\_\_\_

Presence or absence of chemosis (0 = absence; 1 = presence):

right eye \_\_\_\_\_

left eye \_\_\_\_\_

See Figure B.2.



### Key

R right eye

L left eye

**Figure B.2 — Method for recording (conjunctival areas) quadrants affected by conjunctival redness (0 = absence; 1 = presence)**


## B.8 Palpebral conjunctival observations

The severity of the maximal palpebral conjunctival response should be documented according to the following scale:

0 = none	uniform satin appearance of the conjunctiva
1 = trace	slight conjunctival injection without texture

- |              |   |
|--------------|---|
| 2 = mild     | mild or scattered papillae/follicles less than 1 mm in diameter   |
| 3 = moderate | a) significant papillae/follicles less than 1 mm in diameter, and/or marked conjunctival injection<br>b) staining of the top of one papilla |
| 4 = severe   | a) localized or generalized papillae/follicles 1 mm or more in diameter<br>b) staining of the top of more than one papilla                  |

The location of the maximal palpebral conjunctival response should be recorded for each of the six lid areas (see Figure B.3).



**Key**

- R right eye lid  
L left eye lid

**Upper lid**

- 1 S = superior tarsal conjunctiva  
2 C = middle tarsal conjunctiva  
3 I = inferior tarsal conjunctiva  
4 N = nasal tarsal conjunctiva  
5 T = temporal tarsal conjunctiva

**Lower lid (not shown)**

- 6 L = lower lid conjunctiva

**Figure B.3 — Upper lid areas**

**B.9 Anterior segment inflammation**

- |                        |                          |          |             |
|------------------------|--------------------------|----------|-------------|
| Endothelial dusting    | <input type="checkbox"/> | 0 = none | 1 = present |
| Anterior chamber flare | <input type="checkbox"/> | 0 = none | 1 = present |
| Keratitic precipitates | <input type="checkbox"/> | 0 = none | 1 = present |
| Hypopyon               | <input type="checkbox"/> | 0 = none | 1 = present |

## **Annex C** (informative)

### **The evaluation of visual, refractive and lens performance and subject acceptance**

#### **C.1 General**

The following classifications should be considered whenever the procedure is included in the CIP.

#### **C.2 Visual performance**

To assess visual performance visual acuity should be measured.

Traditionally, Snellen charts have been used to measure visual acuity, but they incorporate unequal steps between successive lines. The use of LogMAR progression visual acuity (VA) charts with equal steps between successive lines is recommended. Severe loss in visual performance should be a two-line or more loss on the LogMAR progression scale or its Snellen equivalent.

In those cases where a separate claim is made for a near-vision refractive effect, near visual acuity using a reduced LogMAR or Snellen chart or reading a near chart should be recorded.

Optionally low-contrast visual acuity, contrast sensitivity and visual performance measurement in the presence of a glare source may also be tested.

#### **C.3 Refractive performance**

Refractive changes (absolute mean spherical and cylindrical values) from baseline to the final visit should be provided.

#### **C.4 Keratometric measurement**

The keratometric findings should be reported as either the corneal radius in each principal meridian or the corneal power in each principal meridian.

#### **C.5 Lens fitting characteristics**

##### **C.5.1 General**

The lens fitting characteristics should be assessed to evaluate the on-eye performance using the following classification.

##### **C.5.2 Lens position**

Lens centration for the eye in primary position (relaxed, looking straight ahead) should be recorded on a three-point scale as follows:

- 0 = optimal lens centration
- 1 = acceptable decentration
- 2 = unacceptable decentration

### **C.5.3 Lens movement**

Lens movement should be recorded:

- a) for the eye in the primary position immediately after the blink;
- b) for the recovery movement following digitally applied lower lid margin push-up with the lower lid as follows:
  - 2 = reduced movement unacceptable
  - 1 = reduced movement acceptable
  - 0 = optimal movement
  - +1 = excessive movement acceptable
  - +2 = excessive movement unacceptable

## **C.6 Lens surface characteristics**

### **C.6.1 Front surface wettability**

Wettability should be recorded according to the following scale:

- 0 = a smooth uniformly reflecting surface
- 1 = a coarse hazy surface which seems resolved momentarily with each blink and becomes exacerbated with staring
- 2 = one stable dry (non-wetting) area of some magnitude
- 3 = more than one stable dry (non-wetting) area of some magnitude
- 4 = non-wettable lens surface

### **C.6.2 Front surface deposits**

Deposits should be recorded according to the following scale:

- 0 = absent, clean surface
- 1 = very slight, only visible after tear film drying
- 2 = slight, visible deposits easily removable
- 3 = moderate, deposits adherent and not removable
- 4 = severe, non-removable deposits and comfort affected

NOTE Observed under low slit lamp magnification.

### **C.6.3 Back surface deposits**

Deposits should be recorded according to the following scale:

0 = absent, clean surface

1 = very slight, 3 spots or less of moving particles

2 = slight, up to 10 spots of moving particles

3 = moderate, 3 or less non-moving deposits adherent to lens

4 = severe, 4 or more deposits adherent to the lens and/or corneal indentation

NOTE Observed under low slit lamp magnification.

## **C.7 Subjective acceptance**

### **C.7.1 Comfort**

Comfort should be recorded according to the following scale:

0 = excellent, cannot be felt

1 = very comfortable, just felt occasionally

2 = comfortable, noticeable but not irritating

3 = slightly uncomfortable, just irritating or annoying

4 = very uncomfortable, very irritating or annoying

5 = causes pain, lens cannot be tolerated

### **C.7.2 Vision**

Vision should be recorded according to the following scale:

0 = excellent, cannot notice any visual loss

1 = very good, just noticeable and very occasional reduction

2 = good, occasional noticeable but acceptable reduction

3 = poor, noticeable but acceptable reduction

4 = very poor, marked and unacceptable reduction

5 = unacceptable, lens cannot be worn

### **C.7.3 Handling**

Handling should be recorded according to the following scale:

0 = excellent, no problems with lens insertion and removal

1 = very good, occasional difficulty with lens insertion and removal

2 = good, some problems but insertion and removal usually successful

3 = poor, difficult and very occasional unsuccessful insertion and removal

4 = very poor, difficult and occasional unsuccessful insertion and removal

5 = unmanageable, lenses impossible to handle

## Bibliography

- [1] ISO 9001, *Quality management systems — Requirements*
- [2] ISO 13485, *Medical devices — Quality management systems — Requirements for regulatory purposes*





---

---

**ICS 11.040.70**

Price based on 26 pages



# British Standards Institution (BSI)

BSI is the national body responsible for preparing British Standards and other standards-related publications, information and services.

BSI is incorporated by Royal Charter. British Standards and other standardization products are published by BSI Standards Limited.

## About us

We bring together business, industry, government, consumers, innovators and others to shape their combined experience and expertise into standards-based solutions.

The knowledge embodied in our standards has been carefully assembled in a dependable format and refined through our open consultation process. Organizations of all sizes and across all sectors choose standards to help them achieve their goals.

## Information on standards

We can provide you with the knowledge that your organization needs to succeed. Find out more about British Standards by visiting our website at [bsigroup.com/standards](http://bsigroup.com/standards) or contacting our Customer Services team or Knowledge Centre.

## Buying standards

You can buy and download PDF versions of BSI publications, including British and adopted European and international standards, through our website at [bsigroup.com/shop](http://bsigroup.com/shop), where hard copies can also be purchased.

If you need international and foreign standards from other Standards Development Organizations, hard copies can be ordered from our Customer Services team.

## Subscriptions

Our range of subscription services are designed to make using standards easier for you. For further information on our subscription products go to [bsigroup.com/subscriptions](http://bsigroup.com/subscriptions).

With **British Standards Online (BSOL)** you'll have instant access to over 55,000 British and adopted European and international standards from your desktop. It's available 24/7 and is refreshed daily so you'll always be up to date.

You can keep in touch with standards developments and receive substantial discounts on the purchase price of standards, both in single copy and subscription format, by becoming a **BSI Subscribing Member**.

**PLUS** is an updating service exclusive to BSI Subscribing Members. You will automatically receive the latest hard copy of your standards when they're revised or replaced.

To find out more about becoming a BSI Subscribing Member and the benefits of membership, please visit [bsigroup.com/shop](http://bsigroup.com/shop).

With a **Multi-User Network Licence (MUNL)** you are able to host standards publications on your intranet. Licences can cover as few or as many users as you wish. With updates supplied as soon as they're available, you can be sure your documentation is current. For further information, email [bsmusales@bsigroup.com](mailto:bsmusales@bsigroup.com).

## BSI Group Headquarters

389 Chiswick High Road London W4 4AL UK

## Revisions

Our British Standards and other publications are updated by amendment or revision.

We continually improve the quality of our products and services to benefit your business. If you find an inaccuracy or ambiguity within a British Standard or other BSI publication please inform the Knowledge Centre.

## Copyright

All the data, software and documentation set out in all British Standards and other BSI publications are the property of and copyrighted by BSI, or some person or entity that owns copyright in the information used (such as the international standardization bodies) and has formally licensed such information to BSI for commercial publication and use. Except as permitted under the Copyright, Designs and Patents Act 1988 no extract may be reproduced, stored in a retrieval system or transmitted in any form or by any means – electronic, photocopying, recording or otherwise – without prior written permission from BSI. Details and advice can be obtained from the Copyright & Licensing Department.

## Useful Contacts:

### Customer Services

**Tel:** +44 845 086 9001

**Email (orders):** [orders@bsigroup.com](mailto:orders@bsigroup.com)

**Email (enquiries):** [cservices@bsigroup.com](mailto:cservices@bsigroup.com)

### Subscriptions

**Tel:** +44 845 086 9001

**Email:** [subscriptions@bsigroup.com](mailto:subscriptions@bsigroup.com)

### Knowledge Centre

**Tel:** +44 20 8996 7004

**Email:** [knowledgecentre@bsigroup.com](mailto:knowledgecentre@bsigroup.com)

### Copyright & Licensing

**Tel:** +44 20 8996 7070

**Email:** [copyright@bsigroup.com](mailto:copyright@bsigroup.com)



...making excellence a habit.™